Pharma channel feed

Es­pe­ri­on's goldilocks cho­les­terol fight­er wins FDA ap­proval — will its 'tra­di­tion­al' pric­ing ap­proach spur adop­tion?

6 years ago
FDA+

Phar­ma­co­ge­net­ics: FDA re­leas­es ta­ble of gene-drug in­ter­ac­tions

6 years ago
FDA+

Don't let Ab­b­Vie fool FTC with an easy di­vesti­ture, plead crit­ics in lat­est at­tack on $63B Al­ler­gan buy­out

6 years ago
Deals

Auste­do, Teva's bright spot as it ex­e­cutes turn­around, fails two Touret­te's tri­als

6 years ago

As blue­bird makes com­mer­cial progress in Eu­rope, US ap­pli­ca­tion for Zyn­te­glo suf­fers de­lay

6 years ago
FDA+

For­mer No­var­tis ex­ec pleads guilty to gener­ic price fix­ing

6 years ago

New en­tries, price hikes spur changes among the 20 most ex­pen­sive drugs — though not the kind politi­cians like to see

6 years ago

Coro­n­avirus out­break clouds As­traZeneca's Q4 re­sults and 2020 out­look

6 years ago
R&D
Coronavirus

The list of the 11 block­busters-to-be in line for a 2020 launch high­light agony and ec­sta­sy of drug R&D

6 years ago

8 years af­ter its OK, Ei­sai yanks its flail­ing obe­si­ty drug from the mar­ket af­ter FDA flagged high­er can­cer rate

6 years ago
FDA+

Roche scores its first PD-L1 win in Chi­na, go­ing straight for SCLC niche

6 years ago
China

Af­ter FDA hold and tri­al fail­ure, Ipsen writes down its big ac­qui­si­tion — but they're not giv­ing up

6 years ago

Af­ter years of busi­ness and law­suit-fu­eled de­cline, is a Te­va turn­around in sight?

6 years ago

No­var­tis chris­tens new UK HQ in West Lon­don, kick­ing off its big in­clisir­an CV tri­al

6 years ago
People
R&D

Catch­ing up with Roche, Mer­ck racks up pos­i­tive da­ta in front­line triple neg­a­tive breast can­cer

6 years ago
R&D

Lil­ly, No­vo Nordisk fight in­sulin biosim­i­lars with tweaks to FDA draft guid­ance

6 years ago
FDA+

With block­buster dreams, Ex­elix­is is look­ing for some re­demp­tion for cabo in prostate can­cer. It won’t be easy

6 years ago
R&D

Record lev­els of VC fi­nanc­ing and R&D boom left bio­phar­ma com­pa­nies clam­or­ing for space. How bad is it?

6 years ago

Bio­gen shares rock­et up as My­lan's chal­lenge to Tec­fidera patents is slapped down

6 years ago

It's not just about Keytru­da, Mer­ck in­sists, as it carves out as­sets worth $6.5B in­to new com­pa­ny

6 years ago
Deals
R&D

Too slow to warn: Sanofi in­dict­ed over old an­ti-epilep­tic drug tied to birth de­fects

6 years ago
FDA+

Gilead surges wild­ly as world scram­bles to counter a like­ly coro­n­avirus pan­dem­ic while GSK pitch­es in on vac­cine R&D cam­paign

6 years ago
Coronavirus

Aim­mune wins ap­proval for peanut im­munother­a­py, charges 10k+

6 years ago
FDA+

Biotech was big in 2019, but here's one record no one want­ed to see bro­ken: Most bank­rupt­cies

6 years ago
First page Previous page 256257258259260261262 Next page Last page
A service from the Financial Times